Payer Needs and Strategies for Evaluating and Covering PDTs

Panelists delve into the data and the cost-saving evidence required by payers to cover prescription digital therapeutics (PDTs), outline the decision-making process followed by payers, and share best practices observed in real-world to ensure the successful implementation of PDTs.

EP: 1.Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Now Viewing

EP: 2.Payer Needs and Strategies for Evaluating and Covering PDTs

EP: 3.Payers Review Process and Effective Strategies for PDT Coverage

EP: 4.Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

EP: 5.Dawn of the Age of Adopting PDTs

EP: 6.Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

EP: 7.Evolving Commercialization and Distribution Models for PDTs

EP: 8.Promoting Appropriate PDT Prescribing Through Provider Education and Support

EP: 9.Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

EP: 10.Optimizing Benefit Design and Implementation for Improved PDT Access

EP: 11.PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Related Videos

Related Content

Advertisement

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).

Related Content

Advertisement

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).